TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00064753

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High Dose Multivitamin
Description: Vitamin B6 (Pyridoxine HCl): 50 mg Folic acid: 5.0 mg Vitamin B12: 1.0 mg Vitamin B1 (Thiamine HNO3): 1.5 mg Vitamin B2 (Riboflavin): 1.5 mg Vitamin C (Ascorbic Acid): 60 mg d-Biotin: 300 mcg Niacinamide: 20 mg Pantothenic Acid Calcium Pantothenate): 10 mg

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Low Dose Multivitamin
Description: Vitamin B6 (Pyridoxine HCl): 1.4 mg Folic acid: 0.0 mg Vitamin B12: 2.0 mcg Vitamin B1 (Thiamine HNO3): 1.5 mg Vitamin B2 (Riboflavin): 1.5 mg Vitamin C (Ascorbic Acid): 60 mg d-Biotin: 300 mcg Niacinamide: 20 mg Pantothenic Acid Calcium Pantothenate): 10 mg
Study: NCT03236207

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test extensively hydrolyzed formula
Description: extensively hydrolyzed formula with HMOs

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control extensively hydrolyzed formula
Description: extensively hydrolyzed formula without HMOs
Study: NCT01174680

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cardiogoniometry
Description: In the course of the project a cardiogoniometry will be carried out during the ambulant or residential hospitalization before the coronary angiography.
Study: NCT02951962

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Twynsta 80/5mg
Description: Hypertension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Twynsta 80/5mg
Description: Hypertension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crestor 20mg
Description: Hyperlipidemia

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crestor 20mg
Description: Hyperlipidemia
Study: NCT02636959

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: saline irrigation
Description: HVSI (NeilMed® Sinus Rinse™) versus LVSI (Salinex®) in the early post-operative management in patients with chronic rhinosinusitis. Both are a saline rinse spray.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: saline irrigation
Description: HVSI (NeilMed® Sinus Rinse™) versus LVSI (Salinex®) in the early post-operative management in patients with chronic rhinosinusitis. Both are a saline rinse spray.
Study: NCT00976664

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Shoe orthotic
Description: Shoe orthotics are devices worn in the shoe to modify the patient's stance and gait.

Intervention type: DEVICE
Group type: OTHER
Intervention: Shoe Orthotic Wait Group
Description: This group receives the custom-made shoe orthotics at week 6 of the 12 week treatment program rather than week 1.
Study: NCT03834870

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual cOaching in making Informed Choices on Elder Mistreatment Self-Disclosure (VOICES)
Description: Virtual cOaching in making Informed Choices on Elder Mistreatment Self-Disclosure (VOICES) screening tool.
Study: NCT03117452

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Visual Training
Description: The computerized visual training (VT) program that is being evaluated was developed by Aaron Seitz, who is a co-investigator on this project; it includes 1) ULTIMEYES, which targets broad-based visual functions, including low-level processes (e.g., visual acuity, contrast sensitivity), and 2) visual perceptual organization exercises, which target mid-level visual processes. Both elements of the program also involve higher-level visual functions, such as visual search and visual attention.
Study: NCT02731742

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MK-1966
Description: MK-1966 administered as an intravenous (IV) infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MK-1966
Description: MK-1966 administered as an intravenous (IV) infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MK-1966
Description: MK-1966 administered as an intravenous (IV) infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MK-1966
Description: MK-1966 administered as an intravenous (IV) infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MK-1966
Description: MK-1966 administered as an intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SD-101
Description: SD-101 administered as an intratumoral (IT) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SD-101
Description: SD-101 administered as an intratumoral (IT) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SD-101
Description: SD-101 administered as an intratumoral (IT) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SD-101
Description: SD-101 administered as an intratumoral (IT) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SD-101
Description: SD-101 administered as an intratumoral (IT) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SD-101
Description: SD-101 administered as an intratumoral (IT) injection
Study: NCT01191112

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Peptide based enteral formula
Description: Sole source nutrition as per HCP
Study: NCT03855501

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mineral trioxide aggregate
Description: Apexification treatment was done with mineral trioxide aggregate

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Calcium hydroxide
Description: Apexification treatment was done with calcium hydroxide
Study: NCT01770327

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Effect of ingestion of different Sugary Beverages on Thirst Sensation
Description: The participants will drink Water (control group),Non-fat Milk, Orange Juice and Iced Tea. The beverages will be presented chilled but without ice in 330 ml portions in opaque plastic containers and participants will be asked to consume the entire amount within 15 min.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Effect of ingestion of different Sugary Beverages on Thirst Sensation
Description: The participants will drink Water (control group),Non-fat Milk, Orange Juice and Iced Tea. The beverages will be presented chilled but without ice in 330 ml portions in opaque plastic containers and participants will be asked to consume the entire amount within 15 min.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Effect of ingestion of different Sugary Beverages on Thirst Sensation
Description: The participants will drink Water (control group),Non-fat Milk, Orange Juice and Iced Tea. The beverages will be presented chilled but without ice in 330 ml portions in opaque plastic containers and participants will be asked to consume the entire amount within 15 min.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Effect of ingestion of different Sugary Beverages on Thirst Sensation
Description: The participants will drink Water (control group),Non-fat Milk, Orange Juice and Iced Tea. The beverages will be presented chilled but without ice in 330 ml portions in opaque plastic containers and participants will be asked to consume the entire amount within 15 min.
Study: NCT05085509

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: US guidance and MB staining
Description: Ultrasound guidance and methylene blue staining

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: US guidance and MB staining
Description: Ultrasound guidance and methylene blue staining
Study: NCT03844009

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Computer integrated debriefing
Description: At the end of each computer-based simulation, the participant had a computer integrated debriefing of his performance during the neonatal resuscitation simulation and a debriefing based on an auto-evaluation of his non-technical skills.
Study: NCT03157531

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: B-Laser™ Atherectomy System
Description: The B-Laser™ is indicated for use for atherectomy of infrainguinal stenoses
Study: NCT00331006

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab by slow intravenous infusion; for participants greater than or equal to 10 kg, 375 mg per m\^2 BSA weekly for 4 weeks; for participants less than 10 kg, 12.5 mg/kg weekly for 4 weeks
Study: NCT02736903

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PennFit mobile individual intervention
Description: PennFit (individual) is a mobile app intervention. Participants received a Fitbit physical activity tracking device and an introductory physical activity promotion session emphasizing the health benefits of physical activity and building skills for daily exercises. Participants used the PennFit app (individual) to record and monitor their own physical activity progress.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PennFit mobile online network intervention
Description: PennFit (online network) is a mobile app intervention. Participants received a Fitbit physical activity tracking device and an introductory physical activity promotion session emphasizing the health benefits of physical activity and building skills for daily exercises. Participants used the PennFit app (online network) to record and monitor their own physical activity progress. They could see both their own information and the profiles and activity logs of the three other women assigned to their network. In addition, they could send messages to the network through an instant chatting tool.
Study: NCT00579813

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone
Description: Pioglitazone 30mg for 2 weeks, then Pioglitazone 45mg for 8 weeks.
Study: NCT03098108

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Concurrent chemo-proton therapy
Description: Proton therapy with simultaneous integrated boost technique Gross tumor volume 70.4 gray (Gy)/ 16 fractions and clinical target volume 44.8 Gy/16 fractions Capecitabine twice a day 825 mg/body square meter
Study: NCT03841188

Intervention type: OTHER
Group type: OTHER
Intervention: Nutritional orientation
Description: Nutritional orientation with emphasis in rich calcium food
Study: NCT02039362

Intervention type: DRUG
Group type: OTHER
Intervention: Tenofovir DF
Description: Tenofovir DF will be started at week 28 of pregnancy and stopped or not, according to the physician's decision, at week 12 after birth
Study: NCT01983761

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine, Clofarabine, Busulfan, ATG, TBI (Myeloablative)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine, Melphalan, ATG (Reduced Intensity)
Study: NCT03968718

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Systematic ePROMs Assessment
Description: Depending on the care setting, eligible patients will be asked to fill in one of the following e-PROMs assessment:~Edmonton symptom assessment scale (ESAS-r) (outpatients)~Distress Thermometer (inpatients)~An ad hoc questionnaire adapted from the Bench-Can and EURACAN projects plus the institutional customer satisfaction survey (patients followed by multidisciplinary teams)
Study: NCT01374750

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Sirolimus

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: m-TOR inhibitor free
Description: calcineurin inhibitors
Study: NCT03603314

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SENS-401
Description: 29 mg dose group: tablets of 14.5 mg, oral route, by mouth, twice a day, during 4 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: placebo, oral route, by mouth, twice a day, during 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SENS-401
Description: 43.5 mg dose groupe: tablets of 14.5 mg, oral route, by mouth, twice a day, during 4 weeks
Study: NCT03151057

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idelalisib 100 MG
Description: 100mg BID beginning on day 90 (+/- 10days) and continuing until day 270 post transplant.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: placebo
Study: NCT03518281

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whole Cell Euglena containing Beta Glucan
Description: Whole Cell Euglena containing \>50% Beta Glucan

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: microcrystalline cellulose, hypromellose, titanium dioxide, water
Study: NCT01316445

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nasal Midazolam
Description: Intranasal and buccal administration of the standard IV formulation of midazolam (5mg/mL), administered via a metered dose sprayer at 0.1mL/spray (i.e. 0.5mg/spray). Administration will be via three sprays in each nostril (for nasal) or three sprays between the cheek and the gum per side (for buccal).
Study: NCT00109473

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: growth hormone
Description: Nutropin AQ 0.075mg/kg/day subcutaneously daily
Study: NCT03368755

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Cardiopulmonary Exercise Testing
Description: Pimax, Pemax, airway pressure at 100 msec after occlusion (P0.1), and Ti and Ttot will be measured by the Micro 5000 device (Medisoft, Sorinnes, Belgium). TTImus will be calculated as (Pimean / Pimax) x (Ti / Ttot), where Pimean is the mean airway pressure resulting from the formula Pimean = 5 x P0.1 x Ti9. RM function will be determined a) prior to CPET, b) during CPET when the anaerobic threshold (AT) will be reached, and c) after CPET, when heart rate (HR) and oxygen consumption will be normalized.
Study: NCT01717053

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate
Description: 1000 mg orally once a day for 6 months.
Study: NCT03368755

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Cardiopulmonary Exercise Testing
Description: Pimax, Pemax, airway pressure at 100 msec after occlusion (P0.1), and Ti and Ttot will be measured by the Micro 5000 device (Medisoft, Sorinnes, Belgium). TTImus will be calculated as (Pimean / Pimax) x (Ti / Ttot), where Pimean is the mean airway pressure resulting from the formula Pimean = 5 x P0.1 x Ti9. RM function will be determined a) prior to CPET, b) during CPET when the anaerobic threshold (AT) will be reached, and c) after CPET, when heart rate (HR) and oxygen consumption will be normalized.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Respiratory Muscle Strength and Endurance
Description: CPET will be performed by the Ultima CPX system (Medgraphics, St. Paul, USA), using a cycle ergometer and according to a standardized protocol. The following parameters will be recorded: total work in Watts, maximum HR, maximum oxygen consumption (VO2max), AT indices (work, HR, VO2 ) and duration of recovery.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Respiratory Muscle Strength and Endurance
Description: CPET will be performed by the Ultima CPX system (Medgraphics, St. Paul, USA), using a cycle ergometer and according to a standardized protocol. The following parameters will be recorded: total work in Watts, maximum HR, maximum oxygen consumption (VO2max), AT indices (work, HR, VO2 ) and duration of recovery.
Study: NCT04400123

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Famitinib malate
Description: TR group:~The first period，the subjects will be administrated with Famitinib malate in new formulation, then conduct blood collection within 192h; 14 days washout；The second period，the subjects will be administrated with Famitinib malate in old formulation, then conduct blood collection within 192h.~RT group:~The first period，the subjects will be administrated with Famitinib malate in old formulation, then conduct blood collection within 192h; 14 days washout；The second period，the subjects will be administrated with Famitinib malate in new formulation, then conduct blood collection within 192h.
Study: NCT01717053

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Androgen deprivation
Description: LHRH analog (at discretion of treating physician) will be administered over 6 months (for example, leuprolide acetate 22.5mg IM or goserelin acetate 10.8mg SC given every 3 months for 2 doses).

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Daily (Monday-Friday) for 8 weeks, final dose of 75-80 Gy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 5 mg tablet once daily for 6 months.
Study: NCT01460511

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E004 (Epinephrine Inhalation Aerosol) HFA-MDI
Description: E004 (Epinephrine Inhalation Aerosol) HFA-MDI, 125 mcg/inhalation, 2 inhalations QID

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo-HFA
Description: Placebo-HFA, 0 mcg/inhalation, 2 inhalations QID
Study: NCT01464281

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa 2a
Description: Group 1 : 48-week standard treatment by Peginterferon alfa 2a 180µg/week Group 2 : 96-week prolonged treatment by Peginterferon alfa 2a 180µg/week.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Peginterferon alfa 2a
Description: Group 1 : 48-week standard treatment by Peginterferon alfa 2a 180µg/week Group 2 : 96-week prolonged treatment by Peginterferon alfa 2a 180µg/week.
Study: NCT03876392

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: magnetic resonance imaging
Description: Compare bone marrow biopsy with magnetic resonance imaging to detect bone marrow metastases
Study: NCT04129151

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Oral, per protocol pre determined dosage, once a day for 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ganitumab
Description: -Intravenous, per protocol predetermined dosage, twice per cycle
Study: NCT03517345

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Prebiotic
Description: Prebiotic (Inulin+Oligofructose) consumed as 10 g/d in yogurt (200 g/d)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Control
Description: The only yogurt consumed as 200 g/d without prebiotic.
Study: NCT03034551

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial Incentive, Mobile Phone App, and Cellular Scale
Description: Subjects will be provided a cellular-connected digital scale and will be offered $150 to use the app each day to log one daily self-weighing and one medication check-in. Medication check-ins consist of uploading daily photos of pills at the time of self-administration through the Wellth app. If a 2 lb or greater daily increase in weight, or a 5 lb weekly increase in weight is detected in any patient, a UMCPP physician or nurse will be alerted via automatic email and text. A physician or a nurse will then call the patient to assess the patient's symptoms. If there are increasing heart failure symptoms, the physician or nurse will suggest the patient see their doctor within the next 48 hours and will notify the patient's primary care physician and cardiologist.
Study: NCT01788410

Intervention type: PROCEDURE
Intervention: Cryoablation under image guidance
Description: Observing efficacy of cryoablation to nerves and facet joints for the treatment of radicular pain and pain resulting from facet joint disease.

Intervention type: DEVICE
Intervention: MRI Seednet Cryotherapy System (Galil Medical)
Description: Observing efficacy of cryoablation to nerves and facet joints for the treatment of radicular pain and pain resulting from facet joint disease.
Study: NCT02303392

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT03708354

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo softgel
Description: One 430 mg olive oil softgel daily for 24 weeks. Each placebo softgel of 430 mg olive oil will contain no tocotrienol or tocopherols at detectable levels.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DeltaGold® Tocotrienol 70%
Description: Each TT softgel (DeltaGold® Tocotrienol 70%) contains 430 mg TT (90% δ-TT+10% γ-TT) with a 70% purity, representing 300 mg TT.
Study: NCT04195542

Intervention type: OTHER
Intervention: Questionnaire
Description: questionnaire assessing knowledge of the need to take vitamin B9 supplementation in women in the periconceptional period and the reasons why this supplementation is carried out or not

Intervention type: OTHER
Intervention: Questionnaire
Description: questionnaire assessing knowledge of the need to take vitamin B9 supplementation in women in the periconceptional period and the reasons why this supplementation is carried out or not
Study: NCT01595022

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo: Flexi ring FR01
Description: Intrauterine device, inserted once for 3 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo: Flexi ring FR20
Description: Intrauterine device, inserted once for 3 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo: Ultra low dose levonorgestrel contraceptive system (LCS)
Description: Intrauterine device, inserted once for 3 months
Study: NCT03032302

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Swisse Womens 50+ Ultivite Multivitamin
Description: Single tablet taken once daily

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Swisse Womens 50+ Ultivite Multivitamin
Description: Single tablet taken once daily
Study: NCT00109473

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cortecosteroid
Description: As prescribed by the referring gastroenterologist
Study: NCT02495727

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Step-reduction
Description: Participants will reduce the number of steps they take each day to less than 1, 500 for two weeks, using a pedometer to monitor their daily step count.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Step-reduction
Description: Participants will reduce the number of steps they take each day to less than 1, 500 for two weeks, using a pedometer to monitor their daily step count.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Step-reduction
Description: Participants will reduce the number of steps they take each day to less than 1, 500 for two weeks, using a pedometer to monitor their daily step count.
Study: NCT03032302

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Holland and Barrett Triple Strength Omega-3 Fish Oil
Description: Single capsule taken once daily

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Holland and Barrett Triple Strength Omega-3 Fish Oil
Description: Single capsule taken once daily
Study: NCT00086268

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zoledronic acid